Nokia Corp vs Nuwellis Inc — how do they compare? Nokia Corp trades at $11.01 (market cap $56.70B), while Nuwellis Inc trades at $2.94 (market cap $1.09M). The key difference: Nokia Corp is far larger — about 52018.3× Nuwellis Inc's market cap, and Nokia Corp pays a 1.63% dividend while Nuwellis Inc pays none. Which is the better fit depends on your goals.
| NOK | NUWE | |
|---|---|---|
Market Cap | $56.70B | $1.09M |
Sector | Technology | Technology |
52-Week High | $16.83 | $527.46 |
52-Week Low | $4.05 | $2.80 |
Enterprise Value | $53.51B | -$722.58K |
Dividend Yield | 1.63% | — |
Signals from Pluang's Aura AI — not financial advice
Nokia (NOK) trades at $10.65, up 5.24% on the day, with a bullish analyst consensus price target of $18.00 representing significant upside. Recent earnings show mixed results with a Q1 2026 miss but Q3 and Q4 2025 beats. The company is pivoting toward AI and 5G infrastructure, evidenced by new partnerships and strong revenue growth in these segments. Technical indicators are mixed, with oscillators bullish but moving averages bearish, suggesting near-term consolidation.
The outlook is cautiously optimistic, driven by AI networking demand and strategic deals, but risks include intense competition and execution challenges. Valuation appears stretched with a P/E of 63.22, requiring sustained earnings growth to justify current levels. The stock offers potential for long-term growth if AI initiatives deliver, but near-term volatility is likely.
NUWE trades at $3.00, up 5.26% over 24 hours, following a recent 35:1 reverse stock split effective June 26, 2026. The stock shows a bearish technical signal with all moving averages indicating sell. Fundamentally, the company reported a net loss of $17.52M in 2025, with negative profit margins, though revenue grew to $8.27M. Recent news highlights expansion in pediatric care and a $6M public offering closed in June 2026.
Outlook remains challenging due to persistent losses and high cash burn, but strategic initiatives in pediatric cardiorenal care and new patents offer growth potential. Key risks include negative ROE, reliance on financing, and competitive pressures. Analyst consensus is split evenly between Buy and Hold, reflecting cautious optimism amid financial headwinds.
Trailing returns across standard periods
Nokia is a leading vendor in the telecommunications equipment industry. The company's network business derives revenue from selling wireless and fixed-line hardware, software, and services. Nokia's technology segment licenses its patent portfolio to handset manufacturers and makes royalties from Nokia-branded cellphones. The company, headquartered in Espoo, Finland, operates on a global scale, with most of its revenue from communication service providers.
Read more on NOK →Nuwellis, Inc. is a medical device company focused on developing and commercializing fluid management solutions. The company's primary product is an ultrafiltration system used in hospitals to remove excess fluid from patients with fluid overload, often associated with conditions such as heart and kidney failure. Nuwellis aims to improve patient outcomes and reduce healthcare costs through its specialized, innovative therapies.
Read more on NUWE →